Bufexamac is a non-steroidal anti-inflammatory drug (NSAID) under the market name Droxaryl, Malipuran, Paraderm and Parfenac. It is typically administered topically for the treatment of subacute and chronic eczema of the skin, including atopic eczema and other inflammatory dermatoses, as well as sunburn and other minor burns, and itching. It has also been used in suppositories in combination with local anaesthetics indicated for haemorrhoids. The use of bufexamac has been discontinued in Canada and the United States, which may be due to undetermined clinical efficacy and a high prevalence of contact sensitization [A32822]. Bufexamac was also withdrawn by the EMA in April 2010.
Synonyms
Bufexamic acid
p-Butoxyphenylacetohydroxamic acid
Bufexamac
4-Butoxy-N-hydroxybenzeneacetamide
4-Butoxyphenylacetohydroxamic acid
Acide p-butoxyphenylacethydroxamique
bufexamaco
bufexamacum
2-(p-Butoxyphenyl)-acetohydroxamic acid
Brand Names
Norfemac Ointment - 5%
Norfemac Cream - 5%
Indication
Indicated for the treatment of various skin conditions, such as atopic eczema and other inflammatory dermatoses.
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
